Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523765 · ClinicalTrials.gov registry record · Phase 2
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
A Phase 2 study, sponsored by Priovant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT05523765: Completed Phase 2 study, sponsored by Priovant Therapeutics.
NCT05523765 is a Phase 2 study that has completed, run by Priovant Therapeutics. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05523765, a Phase 2 study, has completed, sponsored by Priovant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
Primary Outcome
Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs, laboratory evaluation for hematology, blood chemistry, and urinalysis; vital signs; electrocardiograms (ECGs); and physical examinations. The investigator will determine whether the change is clinically meaningful.
Interventions
- DRUG Brepocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 2 |
What the finished NCT05523765 record still lists
NCT05523765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Brepocitinib is the first listed.
NCT05523765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05523765 about?
NCT05523765 is a clinical study titled "A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis". This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
What is the current status of trial NCT05523765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2022-11-14. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05523765?
The interventions under investigation include: Brepocitinib (DRUG).
Who is sponsoring clinical trial NCT05523765?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05523765's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI